Reduced telomere length in rheumatoid arthritis is independent of disease activity and duration

Sophia E Steer, Frances M K Williams, Bernet Kato, Jeffry P Gardner, Paul J Norman, Margaret A Hall, Masayuki Kimura, Robert Vaughan, Abraham Aviv and Tim D Spector

Ann Rheum Dis 2007;66:476-480; originally published online 17 Nov 2006; doi:10.1136/ard.2006.059188

Updated information and services can be found at:
http://ard.bmj.com/cgi/content/full/66/4/476

References
This article cites 22 articles, 6 of which can be accessed free at:
http://ard.bmj.com/cgi/content/full/66/4/476#BIBL

Rapid responses
You can respond to this article at:
http://ard.bmj.com/cgi/eletter-submit/66/4/476

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Notes

To order reprints of this article go to:
http://www.bmjournals.com/cgi/reprintform

To subscribe to Annals of the Rheumatic Diseases go to:
http://www.bmjournals.com/subscriptions/
Reduced telomere length in rheumatoid arthritis is independent of disease activity and duration

Sophia E Steer, Frances M K Williams, Bernet Kato, Jeffry P Gardner, Paul J Norman, Margaret A Hall, Masayuki Kimura, Robert Vaughan, Abraham Aviv, Tim D Spector

Background: Rheumatoid arthritis (RA) is associated with reduced lifespan and shortened telomere length in lymphocytes, but the mechanism underlying this is unclear. Telomere loss in white blood cells (WBC) is accelerated by oxidative stress and inflammation in vitro. It was postulated that the accelerated WBC telomere shortening in RA occurs as a result of exposure to chronic inflammation.

Objectives: To measure telomere terminal restriction fragment (TRF) length in a large cohort of RA cases and healthy controls, to explore associations of TRF length with features of disease and with RA-associated HLA-DRB1 alleles.

Methods: WBC and TRF length were measured by Southern blot in DNA from 176 hospital-based RA cases satisfying the 1987 American College of Rheumatology criteria and from 1151 controls. TRF length was compared between cases and controls, and the effects of disease duration, severity and HLA-DRB1 alleles encoding the shared epitope (SE) were assessed.

Results: Age- and sex-adjusted TRF length was significantly shorter in RA cases compared with controls (p=0.001). There was no association between age- and sex-adjusted TRF length and disease duration, C reactive protein or Larsen score. The presence of one or more SE-encoding alleles was associated with reduced adjusted TRF length in RA cases (SE positive vs SE negative cases, p=0.038), but not in controls.

Conclusion: The reduced TRF length in a large group of patients with RA compared with controls has been shown. The reduction is apparently independent of disease duration and markers of disease severity, but is influenced by HLA-DRB1 genotype.

Materials and Methods

Cases of RA satisfying the 1987 American College of Rheumatology diagnostic criteria were recruited consecutively from clinics at Guy’s, St Thomas’ and Lewisham hospitals in London, UK. Details were available on age, sex and disease duration, as well as parameters of disease severity such as rheumatoid factor status, Larsen Score of hand radiographs, disease-modifying anti-rheumatic drug (DMARD) usage (from a retrospective review of patients’ records) and modified Health Assessment Questionnaire (mHAQ) scores. Single measurements of CRP and disease activity scores (DAS28) were also available. Healthy controls were obtained from the Twins UK Adult Twin Registry, which has recruited healthy twin volunteers through national media campaigns. This cohort has been shown to be similar to the general population for age-related traits. For historical reasons, the cohort is predominantly female. Both ethical approval and written informed consent to participate were obtained. Genomic DNA was extracted from peripheral WBC using a standard phenol/chloroform method. DNA samples were checked for quality and integrity before duplicate measurements of the length of the terminal restriction fragments (TRF), obtained by the Southern blot method as detailed elsewhere. The coefficient of variation of the TRF length in this study was 0.92%. Twin DNA TRF length was measured as part of ongoing studies of WBC telomeres. Measurements in cases and controls were

Abbreviations: CRP, C reactive protein; DAS28, disease activity score calculated using 28 joint count; DMARD, disease-modifying anti-rheumatic drug; mHAQ, modified Health Assessment Questionnaire; RA, rheumatoid arthritis; SE, shared epitope; TRF, terminal restriction fragment; WBC, white blood cell
performed in the same laboratory. Briefly, DNA samples were digested overnight and resolved on 5% agarose gel at 50 V. After 16 h, the DNA was depurinated for 30 min, denatured for 30 min and neutralised for 30 min. The DNA was transferred for 1 h to a positively charged nylon membrane, then hybridised with the telomeric probe (digoxigenin 3'-end labelled 5'- (CCTAAA)_3) overnight in 5x SSC 0.1% Sarkosyl, 0.02% sodium dodecyl sulphate and 1% blocking reagent. After washing 3 times for 15 min, the digoxigenin-labelled probe was detected by the digoxigenin luminescent detection procedure and exposed on x ray film. Each DNA sample was measured in duplicate. 

Class II human leucocyte antigen typing in RA cases and a subset of controls was performed using sequence-specific primers. A single twin was selected at random as a control from each of 1204 twin pairs. Standard multiple regression techniques were used to investigate associations between TRF length and age, and age-adjusted TRF length with clinical features. Associations between categorical variables and TRF length, adjusting for age and other covariates, were assessed using analyses of covariance.

**RESULTS**

**General characteristics of the subjects**

Complete data on TRF length and disease variables were available for 176 cases. The mean age of the cases was significantly greater than that of controls (63.8 vs 48.2 years; p<0.001). The proportion of males in our RA cases (16.5%) was greater than that in controls (5.6%; p<0.001). Current smokers made up similar proportions of both cases (28%) and controls (27%), but there was a higher proportion of ex-smokers among cases (39.8% vs 17.2%; p<0.001).

**TRF length in cases and controls**

Figure 1 shows the relationship between TRF length and age in all subjects. Overall TRF length decreased similarly with age in both groups with a correlation of −0.398 in cases and −0.382 in controls. At all age points, RA cases displayed lower mean TRF length than controls, with a mean difference of 369 bp. TRF length was longer in women than in men (6.93 vs 6.36 kb; p<0.001 after adjusting for age). This sex difference was present in both RA cases (females 6.6 kb; males 6.37 kb; p = 0.046, age adjusted) and controls (females 6.98 kb; males 6.33 kb; p<0.001, age adjusted). Therefore, we adjusted for sex as well as age in subsequent analyses. The mean age- and sex-adjusted TRF length of cases was significantly shorter than that of controls, 6.62 kb vs 6.93 kb, p<0.001 (fig 2). Adjustment for smoking status did not alter the relationship with TRF length (data not shown).

**TRF length and RA features**

Linear regression analysis of RA cases showed that, taken individually, greater age (p<0.001), male sex (p = 0.014) and longer disease duration (p = 0.042) were all associated with reduced TRF length, while smoking status was not. Multivariate regression analysis showed that disease status, age and male sex were all independently associated with reduced TRF length (table 1).

If telomere attrition in RA occurs as a result of cell exposure to chronic inflammation, some form of dose–response relationship with disease duration, severity or markers of the acute phase response may be expected. However, there was no association between disease duration and age- and sex-adjusted TRF length, or with CRP level, DAS28 or mHAQ score. Age- and sex-adjusted TRF length did not differ between cases seropositive and seronegative for rheumatoid factor (6.30 and 6.27, respectively; p = 0.73). The presence of erosive disease also had no clear effect (erosive vs non-erosive (6.31 vs. 6.19); p = 0.36). The Larsen score was significantly associated with disease duration, and, once this was taken into account, no independent effect of Larsen score was seen. We were unable to identify any significant associations between number of DMARDS, NSAIDs or steroids used during the course of disease age- and sex-adjusted TRF length.

**TRF and HLA-DRB1 genotype**

HLA-DRB1 genotype information was available in 170 cases and 128 controls. The presence of one or more copies of the SE (defined by alleles *0401, *0404, *0405, *0408, *0101, *0102, *1001 and *1402) did not influence age- and sex-adjusted TRF length in controls (SE positive vs SE negative controls (6.86 vs 6.83); p = 0.80). In cases, age- and sex-adjusted TRF length was shorter in those positive for the SE (SE positive vs SE negative cases (6.35 vs 6.59); p = 0.038; fig 3A). Comparison of cases and controls by SE status showed that TRF length in SE positive cases of RA was significantly shorter than that in SE positive controls (6.35 vs 6.86 kb; p<0.001, adjusted as before), with a similar but non-significant trend in those negative for SE (p = 0.092). We found no evidence of a dose–response relationship with the number of SE-encoding alleles. Subgroup analysis by presence of DR1 or DR4 alleles showed no statistically significant differences in adjusted TRF length between DR1 positive and DR4 positive cases, or between DR1 positive and DR4 positive controls (fig 3B). In summary, disease status was the dominant influence on TRF length, but the presence of the SE seemed to compound this effect in RA cases.

**DISCUSSION**

Patients with RA have reduced life expectancy. Recently, this observation has been attributed to an excess of cardiovascular deaths. Telomere length is a putative marker of biological age and has been shown to be reduced in WBC from patients with age-related diseases such as Alzheimer’s dementia, atherosclerosis and hypertension, and also to be associated with early mortality in the elderly in some but not all studies. Two previous studies have suggested that telomere length is reduced in RA. Our data, based on a larger dataset than either of the previously published studies, show two important findings: (1) that WBC telomere length declines in a linear fashion in both RA cases and controls, in contrast with the findings of Koetz et al; (2) that age- and sex-adjusted WBC telomere length in RA cases is considerably shorter than in controls. The difference is equivalent to 15 times the annualised rate of WBC telomere length loss in age-adjusted controls extrapolated from cross-sectional data.

Our data do not support the hypothesis that inflammation in RA is the predominant factor promoting WBC telomere shortening, but show that telomere length measured cross-sectionally is reduced independent of RA duration and severity. That the regression lines of TRF length against age for cases and controls are parallel (fig 1) suggests that this difference in telomere length is present at a young age and it seems not to increase with age. These observations are consistent with reduced WBC telomere length in RA being an early, and possibly disease-predisposing, process rather than occurring secondary to disease. We note, however, that these tentative conclusions are based on cross-sectional analysis. Given the wide variation in age-adjusted WBC telomere length, a longitudinal study focusing on WBC subsets over an extended period would be the ideal design, but for statistical reasons this study is likely to have underestimated, rather than overestimated, changes in telomere length with age. All leucocyte subsets contribute to pathogenesis of RA, with both distinct and interacting pathways, and possibly we have failed to detect
been shown and this might also have reduced the sensitivity of
coefficient of variation of lymphocyte TRF length with age has
will be required to draw firm conclusions. An increase in the
length in whole peripheral blood might have reduced our ability
to detect a difference, and further experiments on WBC subsets
HLA-DRB1 genotypes, the fact that we measured the WBC TRF
distribution of white cell subpopulations between different
older age groups. Although there are no data to suggest altered
DR4 positive and DR4 negative controls in young adulthood,
showed that HLA-DR4 was associated with reduced telomere
length in peripheral blood T-cells and granulocytes in a small
sample of young healthy controls. Our data, from a much larger
sample of older subjects, do not support an effect of HLA-DRB1
genotype on telomere length in peripheral blood WBC of
healthy controls. This has many possible explanations including
the potential for greater influence of environmental exposures
with age; Schonland et al.19 showed maximal difference between
DR4 positive and DR4 negative controls in young adulthood,
with no influence of genotype on annual rate of telomere loss in
older age groups. Although there are no data to suggest altered
distribution of white cell subpopulations between different
HLA-DRB1 genotypes, the fact that we measured the WBC TRF
length in whole peripheral blood might have reduced our ability
to detect a difference, and further experiments on WBC subsets
will be required to draw firm conclusions. An increase in the
coefficient of variation of lymphocyte TRF length with age has
been shown and this might also have reduced the sensitivity of
our analysis.23 We did detect an effect of HLA-DRB1 genotype
on TRF length in RA cases. Our findings are consistent with
those of Schonland et al.19 who identified short telomeres in
lymphocytes and granulocytes of DR4 positive RA cases. We did
not detect a difference between DR4 and DR1 subgroups, but
this analysis did not have sufficient power.

As with any study, there are potential limitations. The RA
cases and controls were not age matched; rather than losing
information by using smaller age-matched subgroups, we
adjusted for age in the analyses. Such an analysis assumes
that TRF length declines linearly with age, a feature suggested
by our large cross-sectional dataset.11 A subgroup analysis of
patients and controls having similar ages, however, gave the
same result. Single measurements of CRP and DAS28 scores
may be criticised as poor surrogates for long-term disease
activity; the Larsen score, however, is considered a good
reflection of cumulative disease burden. Subgroup analysis of
SE negative cases and controls was underpowered, reflecting
the availability of HLA-DRB1 genotypes for only a proportion
of the controls. Another potential limitation is that we did not
have information on weight in RA cases. We have shown raised
BMI to be associated with shorter WBC telomere length,11 and a
gain in BMI to be associated with accelerated WBC telomere
attrition.22 This is not a likely confounder in our results as
patients with RA tend to be lighter than controls, which would
act in the opposite direction and make the groups appear more
similar. Smoking status was not a confounder in this dataset. In
addition, the RA cases analysed here were all hospital
attendees; the findings may be different in RA cases managed
in primary care, which tend to have milder disease.

CONCLUSIONS
This study of RA cases confirms the association of disease with
markedly reduced telomere length in peripheral blood and
shows no clear relationship between TRF length and disease
severity or progression. Our data suggest that the difference
may arise before the clinical diagnosis or during an early phase
of the disease. The findings may point to an underlying
pathogenic mechanism, perhaps reflecting altered WBC

---

Table 1: Multiple regression analysis with terminal restriction fragment length as the dependent variable in RA
cases and controls

<table>
<thead>
<tr>
<th>Covariate</th>
<th>Regression coefficient</th>
<th>p Value</th>
<th>R²</th>
</tr>
</thead>
<tbody>
<tr>
<td>DS</td>
<td>−0.38</td>
<td>&lt;0.001</td>
<td>0.37</td>
</tr>
<tr>
<td>Age</td>
<td>−0.022</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>0.273</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>−0.028</td>
<td>0.72</td>
<td></td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>−0.093</td>
<td>0.293</td>
<td></td>
</tr>
<tr>
<td>SE</td>
<td>0.043</td>
<td>0.581</td>
<td></td>
</tr>
</tbody>
</table>

DS, disease status is coded as 0 and 1 for controls and cases, respectively. Current smoker and ex-smoker data are
with those of subjects who never smoked, respectively. SE represents shared epitope-encoding alleles, and is coded as absent if the
subject carries no SE-encoding allele and as present if the subject carries one or more SE-encoding allele.
maturation pathways, such as thymic T cell production and altered peripheral WBC turnover. In this RA population, WBC telomere length was shorter in those carrying the SE. This suggests that susceptibility to telomere erosion is at least in part determined by HLA-DRB1 or other nearby loci in linkage disequilibrium. It remains possible, therefore, that WBC telomere dynamics (telomere length and attrition rate) will prove to be the functional basis for the association of SE with RA. Telomere length is known to be synchronised (equivalent) between tissues in the newborn, so that individuals with short telomeres in one tissue have short telomeres in other tissues. 24 Telomere length is partially synchronised in adult tissues. 25-27 It will be of interest to determine how the various types of tissue, in addition to WBC and WBC subsets, are influenced in RA. The demonstration of relatively normal TRF length in other tissues from patients with RA would support our current working hypothesis: that an early environmental influence in genetically susceptible individuals results in a prematurely aged immune system and disease. The longitudinal exploration of the role of telomere attrition in WBC subsets is likely to be a fruitful area of research in the pathogenesis of RA.

ACKNOWLEDGEMENTS

Contributions: SES obtained ethics approval, recruited cases, collected clinical data and blood samples, contributed to statistical analysis and drafted the manuscript. FMKW participated in the design and coordination of the study, the statistical analysis and drafting of the manuscript. BK performed statistical analysis and contributed to the manuscript. JPG coordinated exchange between Aviv’s lab and Spector’s group. MK oversaw the TRF length analysis. PJN performed HLA genotyping and interpretation of data. MAH performed sample extraction, HLA genotyping and interpretation of data. RV provided advice on the analysis and interpretation of the HLA data. AA and TDS developed the overall thesis of this research and participated in writing the paper. TDS conceived the study, participated in its design and coordination, and critically reviewed the manuscript. All authors read and approved the final manuscript.

Janet Grumley assisted with patient recruitment and data collection, and Bhaneceta Lad with DNA extractions.

Authors’ affiliations
Sophia E Steer, Margaret A Hall*, Department of Rheumatology, King’s College London School of Medicine at Guy’s, King’s and St Thomas’, London, UK
Frances M K Williams, Bernet Kato, Tim D Spector, Twin Research and Genetic Epidemiology Unit, Kings College London School of Medicine at Guy’s, King’s and St Thomas’, London, UK
Paul J Norman, Department of Structural Biology, Stanford University School of Medicine, Stanford, California, USA
Robert Vaughan, Clinical Transplantation Laboratory, Guy’s and St Thomas Foundation Trust and King’s College, London, UK
Jeffry P Gardner, Masayuki Kimura, Abraham Aviv, The Center of Human Development and Aging, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA

*These authors contributed equally to this work.

Competing interests: None.

REFERENCES
13. Tettamanti M, Orup C, Olerup O. Identification of the HLA-DRB1*04, DRB1*07, and -DQB1*02 alleles by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Hum Immunol 1992;34:64–74.

www.annrheumdis.com

Figure 3. Comparison of age- and sex-adjusted terminal restriction fragment (TRF) length by HLA-DRB1 status in RA cases and controls. DR1, *0101 + 0102; DR4, *0401 + 0404, *0408; neg, negative; pos, positive; SE, shared epitope.

bmjupdates+

bmjupdates+ is a unique and free alerting service, designed to keep you up to date with the medical literature that is truly important to your practice. bmjupdates+ will alert you to important new research and will provide you with the best new evidence concerning important advances in health care, tailored to your medical interests and time demands.

Where does the information come from?
bmjupdates+ applies an expert critical appraisal filter to over 100 top medical journals
A panel of over 2000 physicians find the few ‘must read’ studies for each area of clinical interest

Sign up to receive your tailored email alerts, searching access and more…

www.bmjupdates.com